| # | Title | Journal | Year | Citations |
|---|
| 1 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial | Lancet, The | 2015 | 1,175 |
| 2 | Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study | Annals of Oncology | 2017 | 549 |
| 3 | Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities | Cancer | 1982 | 484 |
| 4 | Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer | JAMA - Journal of the American Medical Association | 2017 | 281 |
| 5 | Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial | Lancet Oncology, The | 2015 | 206 |
| 6 | A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4) | Annals of Oncology | 2017 | 133 |
| 7 | Temporal change in diagnostic criteria as a cause of the increase of malignant melanoma over time is unlikely | International Journal of Cancer | 1991 | 104 |
| 8 | Delays in diagnosis and treatment of breast cancer: a multinational analysis | European Journal of Public Health | 2014 | 98 |
| 9 | Stage I Melanoma of the Limbs: Assessment of Prognosis by Levels of Invasion and Maximum Thickness | Tumori | 1978 | 89 |
| 10 | PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study | British Journal of Cancer | 2019 | 43 |
| 11 | Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study | ESMO Open | 2021 | 40 |
| 12 | COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma | Journal of Clinical Oncology | 2014 | 40 |
| 13 | Kinase mTOR: Regulation and role in maintenance of cellular homeostasis, tumor development, and aging | Biochemistry (Moscow) | 2014 | 33 |
| 14 | A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer | British Journal of Cancer | 2004 | 30 |
| 15 | Newborn Macrosomy And Cancer | Advances in Cancer Research | 1988 | 27 |
| 16 | Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study | Supportive Care in Cancer | 2012 | 27 |
| 17 | A Tale of Two Concepts: Harmonizing the Free Radical and Antagonistic Pleiotropy Theories of Aging | Antioxidants and Redox Signaling | 2018 | 27 |
| 18 | Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma | British Journal of Cancer | 2013 | 25 |
| 19 | Persistence of methylated purines in the dna of various rat fetal and maternal tissues and carcinogenesis in the offspring following a single transplacental dose ofN-methyl-N-nitrosourea | International Journal of Cancer | 1983 | 19 |
| 20 | Nikolai Vasilyevich Lazarev, toxicologist and pharmacologist, comes in from the cold | Trends in Pharmacological Sciences | 1992 | 18 |
| 21 | Laser Therapy of Human Benign and Malignant Neoplasms of the Skin | Acta Radiologica: Therapy, Physics, Biology | 1975 | 13 |
| 22 | Study of postnatal effects of chemopreventive agents on offspring of ethylnitrosourea-induced transplacental carcinogenesis in rats. I. Influence of retinol acetate, α-tocopherol acetate, thiamine chloride, sodium selenite, and α-difluoromethylornithine | Cancer Letters | 1991 | 12 |
| 23 | Adjuvant long-term chemotherapy in complex treatment of operable breast cancer | Cancer | 1974 | 10 |
| 24 | Two bullets to the head and an early winter: fate permits Kutuzov to defeat Napoleon at Moscow | Neurosurgical Focus | 2015 | 8 |
| 25 | Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial | Annals of Oncology | 2016 | 7 |
| 26 | 1401P Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study | Annals of Oncology | 2020 | 7 |
| 27 | Music and longevity | Advances in Gerontology | 2014 | 6 |
| 28 | Mean age of death and longevity for male scientists of different specialties | Moscow University Biological Sciences Bulletin | 2016 | 6 |
| 29 | Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies | Frontiers in Oncology | 2021 | 6 |
| 30 | Clinical and Morphological Correlation of Hodgkin's Disease in Children | Tumori | 1973 | 5 |
| 31 | Hodgkin's disease in children: Clinico-roentgenologic features of the lesion in the chest | Pediatric Radiology | 1976 | 5 |
| 32 | Hodgkin's disease in children: Involvement of lung and pleura | Pediatric Radiology | 1976 | 4 |
| 33 | Exploratory laparotomy and splenectomy in the diagnosis of Hodgkin's disease in children | Journal of Surgical Oncology | 1976 | 4 |
| 34 | Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma. | Journal of Clinical Oncology | 2014 | 4 |
| 35 | Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. | Journal of Clinical Oncology | 2015 | 3 |
| 36 | Comparative Aspects of Pigmented Nevi in Children, Youths and Adults | Tumori | 1978 | 2 |
| 37 | Multi-Arm, Nonrandomized, Open-Label Phase Ib Study to Evaluate Fp1039/Gsk3052230 with Chemotherapy in Nsclc and Mpm with Deregulated Fgf Pathway Signaling | Annals of Oncology | 2014 | 2 |
| 38 | P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC | Journal of Thoracic Oncology | 2017 | 2 |
| 39 | LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN | Annals of Oncology | 2019 | 2 |
| 40 | 379MO Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN | Annals of Oncology | 2020 | 2 |
| 41 | N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) in experimental rat gastrocarcinogenesis : comparative sensibility to MNNG-carcinogenic action of the gland epithelium and the epithelium of experimental endophytic hyperplastic adenomatous structures | Experimental Pathology | 1988 | 1 |
| 42 | Experience of Treating Painful Bone Metastases With Magnetic Resonance Guided Focused Ultrasound | International Journal of Radiation Oncology Biology Physics | 2012 | 1 |
| 43 | Age-related and clinicopathological features of colorectal cancer associated with K-ras gene status | Advances in Gerontology | 2012 | 1 |
| 44 | Droplet digital PCR of circulating tumour DNA for the detection of RAS/BRAF mutation in metastatic colorectal cancer | Annals of Oncology | 2018 | 1 |
| 45 | Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC | Annals of Oncology | 2019 | 1 |
| 46 | Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials | Annals of Oncology | 2019 | 1 |
| 47 | 366MO Osimertinib plus platinum/pemetrexed in newly diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study | Annals of Oncology | 2020 | 1 |
| 48 | Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities | Annals of Oncology | 1982 | 1 |
| 49 | Abstract A166: BELLE-4: A Phase II study of buparlisib and paclitaxel in women with HER2- advanced breast cancer, with or without PI3K pathway activation | Annals of Oncology | 2015 | 1 |
| 50 | Prognostic Factors in Patients with Multiple Myeloma | Hamatologie Und Bluttransfusion | 1992 | 1 |
